Source disclosure: January 30, 2026
MediciNova,Inc. [4875.T]
TOKYO, Jan 30 (Pulse News Wire) – Medicinova,inc. (4875.T) announced today that its Expand Access Protocol (EAP) clinical trial for MN-166 (Ibudastine) targeting Amyotrophic Lateral Sclerosis (ALS) has reached half of its target patient enrollment of 200, with 100 patients now registered across 12 sites as of January 2026.
The study, funded by the U.S. National Institutes of Health (NIH), provides MN-166 treatment access to patients ineligible for the ongoing randomized clinical trial COMBAT-ALS. Additionally, the SEANOBI-ALS study collects important biomarker and clinical outcome data. CEO Hiroyuki Iwajima commented, “We deeply appreciate the participation of patients, their families, healthcare providers, and staff involved in the SEANOBI-ALS study.
We also thank NIH and NINDS for continued support through the Act for ALS program.” He further noted that reaching 100 patient registrations represents significant progress in MN-166’s clinical development and expects positive outcomes towards regulatory approval based on top-line data expected by the end of 2026. The Phase 2b/3 clinical trial COMBAT-ALS, which evaluates MN-166's efficacy and safety against placebo, continues in the U.S. and Canada with 234 patients enrolled. Top-line results from this trial are scheduled for release by the end of 2026.
AI-translated content. 🟢 Confidence: High See terms • Original filing